CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

Similar to pediatric acute myeloid leukemia (AML) the subgroup of biphenotypic acute lymphoblastic leukemia (ALL) is a rare complex entity with adverse outcome, characterized by the surface expression of CD33. Despite novel and promising anti-CD19 targeted immunotherapies such as chimeric antigen re...

Descripción completa

Detalles Bibliográficos
Autores principales: Reusing, Sarah B., Vallera, Dan A., Manser, Angela R., Vatrin, Titus, Bhatia, Sanil, Felices, Martin, Miller, Jeffrey S., Uhrberg, Markus, Babor, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571204/
https://www.ncbi.nlm.nih.gov/pubmed/34398302
http://dx.doi.org/10.1007/s00262-021-03008-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571204/
https://www.ncbi.nlm.nih.gov/pubmed/34398302
http://dx.doi.org/10.1007/s00262-021-03008-0

Ejemplares similares